Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
105.10
(
-1.72%
)
Bitcoin
70,439.01
(
-0.11%
)
News Focus
News Focus
Post# of 257268
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

RockRat

Send PM Follow Ignore
Followers 10
Posts 903
Boards Moderated 0
Alias Born 12/19/2005

RockRat

Re: vinmantoo post# 114819

Tuesday, 02/15/2011 2:16:37 PM

Tuesday, February 15, 2011 2:16:37 PM

Post# of 257268
PRO 140 has shown decent results in studies, but an injectable for HIV = commercial dud, niche market at best for non-responders to other treatments, maybe. Whatever happened to PRO 206, the small molecule entry inhibitor for HepC? They still show the entry inhibitors as preclinical candidates on their pipe chart, but no mention of PRO206 directly.

They announced its selection for clinical development over two years ago. Suspiciously slow. Dubious about PGNX as an investment.

Regards, RockRat
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today